Interestingly, the KDM6A-knockout lung tumors appeared to be more sensitive to EZH2 inhibitor, indicating that NSCLC patients with KDM6A loss may get more benefit from EZH2 inhibition therapy [123]. This evidence concerns the gene KDM6A and non-small cell lung carcinoma.